Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flu Vaccine Shortage Shows Hazards Of Market Concentration – Sen. Leahy

Executive Summary

The Bush Administration should have "learned their lesson" from last year's influenza vaccine shortages, Sen. Patrick Leahy (D-Vt.) says

You may also be interested in...



BIO “Follow-On” Biologics Risk-Based Proposal Would Require Clinical Tests

The Biotechnology Industry Organization's risk-based approach to a regulatory pathway for "follow-on" biologics would include a clinical testing requirement

BIO “Follow-On” Biologics Risk-Based Proposal Would Require Clinical Tests

The Biotechnology Industry Organization's risk-based approach to a regulatory pathway for "follow-on" biologics would include a clinical testing requirement

FDA Approves Use Of Fluarix Under An IND; GSK To Submit BLA In First Half ’05

GlaxoSmithKline plans to establish a presence in the U.S. influenza vaccine market with a BLA submission for Fluarix in the first half of 2005

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel